by Lisa Stiffler on Nov 13, 2026 at 12:51 pmNovember 13, 2026 at 4:38 pm.
Araceli Biosciences, a Portland-area biotech manufacturer, has secured $4.5 million in funding to help commercialize technology and develop new products that support using human cells instead of animal studies to test new drugs.
According to recent reports, the Tigard, Ore., startup offers instruments and software for creating images of cells and automating analysis. Its technologies fall under the umbrella term “New Approach Methodologies,” which includes human-tissue models, computer simulations and AI-based approaches that reduce or avoid experimentation on animals such as mice, rats and monkeys.
It has been revealed that supporters of the methods, known as NAMs, argue that they can yield better outcomes because animals are not a perfect substitute for humans and can generate irrelevant findings. That can lead to costly, time-intensive development of drugs that fail to perform in people. Advocates also promote the alternatives as more humane.
The National Institutes of Health unveiled $84 million in September to build infrastructure for NAMs research at 10 sites nationwide.
“[T]he efforts signal a significant investment into human-based technologies as the future of preclinical science, aiming to make research faster, more predictive, and more directly relevant to human health,” the NIH mentioned in a release.
Araceli noted it has raised a total of $22.7 million from investors. The new round was led by William Cortelyou and included Fluke Venture Partners, according to PitchBook. The company disclosed Thursday that businessman and animal welfare advocate Jeff Swickard was also an investor.
Swickard owns 54 auto dealerships across Western states and is a commercial real estate investor with $250 million invested in Portland properties.
Shawn MacDonald, chief financial officer for Araceli, remarked Swickard’s “support reflects a belief that we share, which is that better science and more humane science go hand-in-hand.”.
Araceli introduced in 2023 as a spinoff from Phoseon Technology, which makes UV LED units for industrial curing and life sciences applications.
In a recent development, the manufacturer stated that companies and institutions using Araceli technology include the Max Planck Institute and Evotec in Germany, the Wertheim UF Scripps Institute in Florida, VALID Therapeutics in Boston, and Ginkgo Bioworks, as well as large pharmaceutical companies. It has 30 employees.
